Mabeck C E, Vejlsgaard R
Infection. 1979;7 Suppl 4:S414-5. doi: 10.1007/BF01639025.
In a double-blind study 1194 patients with bacteriologically diagnosed urinary tract infection were randomly selected for treatment with either 1 g sulphamethizole twice daily, 200 mg trimethoprim twice daily, or 410 mg sulphadiazine plus 90 mg trimethoprim twice daily. All drugs were administered perorally for seven days. Two weeks after commencement of therapy 70% of the patients treated with sulphamethizole, 80% of those treated with trimethoprim and 85% of those treated with sulphadiazine/trimethoprim had sterile urine. After ten weeks 25% of the patients had bacteriuria irrespective of the form of treatment. Side-effects such as skin reactions occurred in 4.1% of the patients treated with trimethoprim alone, in 1.4% of those treated with sulphamethizole and in 3.2% of those treated with trimethoprim/sulphadiazine.
在一项双盲研究中,随机选取1194例经细菌学诊断为尿路感染的患者,分别接受以下治疗:每日两次,每次1克磺胺甲噻二唑;每日两次,每次200毫克甲氧苄啶;或每日两次,每次410毫克磺胺嘧啶加90毫克甲氧苄啶。所有药物均口服给药,疗程为7天。治疗开始两周后,接受磺胺甲噻二唑治疗的患者中有70%尿液无菌,接受甲氧苄啶治疗的患者中有80%尿液无菌,接受磺胺嘧啶/甲氧苄啶治疗的患者中有85%尿液无菌。十周后,无论采用何种治疗方式,25%的患者出现菌尿。单独使用甲氧苄啶治疗的患者中,4.1%出现皮肤反应等副作用;使用磺胺甲噻二唑治疗的患者中,1.4%出现副作用;使用甲氧苄啶/磺胺嘧啶治疗的患者中,3.2%出现副作用。